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In a prospective study of prostate cancer incidence (127 cases), among 22320 Japanese men, sleep duration was associated with
lower risk; the multivariate hazard ratio of men who slept X9h per day compared with those who slept less was 0.48 (95%
confidence interval: 0.29–0.79, P for trend¼0.02).
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Sleep duration is associated with various health outcomes
(Youngstedt and Kripke, 2004) including three observational
studies of sleep duration and breast cancer (Verkasalo et al,
2005; McElroy et al, 2006; Pinheiro et al, 2006). Melatonin, which is
secreted mainly from the pineal gland and plays a role in sleep
duration, is suggested as one of the candidates responsible for the
association in breast cancer (Brzezinski, 1997; Schernhammer and
Schulmeister, 2004) as it influences the synthesis and secretion of
sex hormones by promoting the release of gonadotropin-releasing
hormone (Martin and Klein, 1976; Aleandri et al, 1996).
In relation to melatonin, there have been several observational
studies of night work, shift work or visual impairment, and sex
hormone-related cancers such as prostate or breast (Feychting
et al, 1998; Verkasalo et al, 1999; Kliukiene et al, 2001; Megdal
et al, 2005; Kubo et al, 2006; Conlon et al, 2007; Schwartzbaum
et al, 2007). However, there has been no study of sleep duration
and prostate cancer risk, even though prostate cancer, like breast
cancer, is also a sex hormone-related cancer.
We therefore examined the association between sleep duration
and prostate cancer risk in a population of Japanese men, in whom
the mortality of prostate cancer is increasing (Statistics and
Information Department, Minister’s Secretariat, Ministry of Health
Labour and Welfare of Japan, 2007).
MATERIALS AND METHODS
Details of the Ohsaki National Health Insurance (NHI) Cohort
Study have been described previously (Tsuji et al, 1998; Kuriyama
et al, 2006). Briefly, this prospective cohort study was started in
1994 and included 26481 men aged 40–79 years living in the 14
municipalities of Miyagi Prefecture, northeastern Japan. The
response rate was 94.0% (N¼24895) for the questionnaire that
was self-administered and included items about sleep duration and
other health-related lifestyle factors. The study protocol was
reviewed and approved by the ethics committee of Tohoku
University School of Medicine.
After exclusion of subjects who had withdrawn from the NHI
before follow-up, those who had a history of cancer, those who had
omitted responses for sleep duration, and those who had reported
sleep duration of less than 4h or more than 12h, 22320 subjects
remained. To follow-up participants for mortality and migration,
we reviewed the NHI withdrawal history files for 1995–2001.
Through the Miyagi Prefectural Cancer Registry, we identified 127
incident cases of prostate cancer. During the study period, there
had been no mass screening programme for prostate cancer in this
area. Clinical stage was classified according to the TNM system as
localised (T1–T2), advanced (T3–T4), metastatic (Nþ and/or
Mþ), or unknown.
With regard to the sleep duration, participants answered the
mean integer number of hours of sleep per day during the last
year. Because of the small number who slept for less than 7h and
more than 8h, we categorised sleep duration into three groups:
p6, 7–8, and X9h per day. We estimated hazard ratios (HRs) and
95% confidence intervals (CIs) of prostate cancer incidence
according to sleep duration, using the Cox proportional hazards
model, with adjustment for age and potential confounders. The
continuous P for trend was calculated by treating sleep duration as
a continuous variable, and the categorical P for trend by treating
each category as a continuous variable. Interactions between the
risk and all confounders were tested through the addition of cross-
product terms to multivariate model.
All statistical analyses were performed using SAS statistical
software, version 9.1 (SAS Institute Inc, Cary, NC, USA), and all
those reported were two-sided; differences at P-values of o0.05
were accepted as significant.
RESULTS
Table 1 shows the baseline characteristics of subjects according to
sleep duration. Subjects who slept 9h or more per day (long
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ysleepers) were older, less likely to be employed and married, and
more likely to have a history of disease. Those who slept 6h or less
per day (short sleepers) were more likely to have never smoked
and less likely to walk more than 1h per day.
We found an inverse association between sleep duration and
risk. The HR of prostate cancer in short sleepers was 1.34 (95%
CI: 0.83–2.17) and the HR for long sleepers was 0.48
(95% CI: 0.29–0.79) (P for trend¼0.02). This result did not
change substantially when subjects whose event occurred within 3
years of baseline (N¼46) were excluded and analysis of each
clinical stage (localised or advanced/metastatic) was examined
(Table 2).
In addition, we examined in detail, confounding and effect
modification by age and other covariates on the associations with
sleep duration. No significant interaction was observed between
sleep duration and other confounding factors for risk on a
multiplicative scale (data not shown).
DISCUSSION
In the first study to address the question, we found an inverse
association between sleep duration and the risk of prostate cancer
in Japanese men. There have, however, been three observational
studies of sleep duration and breast cancer risk (McElroy et al,
2006; Pinheiro et al, 2006). Among these, one reported a decreased
risk in long sleepers (Verkasalo et al, 2005), the second reported
no association (Pinheiro et al, 2006), whereas the third reported an
increased risk in long sleepers (McElroy et al, 2006). Among
possible reasons for these differences from our findings (apart
from the site of cancer), McElroy et al (2006) conducted a case–
control study while Pinheiro et al (2006) studied residential nurses
in the United States with rotating shift work and varying timing of
sleep so that generalising from their results may be inappropriate.
Melatonin may be a factor in these inverse associations with sex
hormone-related cancers (Brzezinski, 1997; Schernhammer and
Schulmeister, 2004; Shiu, 2007). A decreased sleep duration results
in a shorter duration of nocturnal melatonin secretion (Wehr,
1991). Melatonin may have an inhibitory effect on gonadal
function, including the synthesis and secretion of sex hormones,
by promoting the release of gonadotropin-releasing hormone
(Martin and Klein, 1976; Aleandri et al, 1996). It also exerts an
antiproliferative effect on prostate and breast cancer cell lines
(Shiu, 2007).
Strengths of the present study include its prospective nature and
its base in the general population. In addition, the Miyagi
Prefectural Cancer Registry is one of the earliest and most
accurate population-based cancer registries in Japan (Takano and
Okuno, 1997); so our data on cancer incidence are considered
sufficiently reliable.
Methodological limitations include the fact that sleep duration
was self-reported. Second, we had no information about sleep
quality, the timing of sleep, the use of sleep medication, the
presence of sleeping disorders or rotating shift work. Such factors
influence sleep duration and thereby might affect the findings.
In conclusion, we have found a significant inverse association
between sleep duration and the risk of prostate cancer incidence in
Japanese men.
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Table 1 Baseline characteristics of the subjects according to sleep
duration
Sleep duration p67 – 8 X9
Number of subjects 2671 15127 4522
Mean age, s.d. (years) 57.7 (11.0) 58.0 (10.4) 64.0 (9.3)
Mean body mass index, s.d. (kgm
 2) 23.7 (3.2) 23.4 (2.9) 23.1 (3.4)
Having history of diseases
a (%) 31.3 29.4 38.9
Employed (%) 59.2 61.0 47.8
Married (%) 80.1 82.2 77.0
Never smoked (%) 19.4 18.2 15.9
Never drank (%) 15.5 16.3 14.8
Walking 1h per day or more (%) 42.6 45.7 43.4
Having family history of cancer (%) 30.0 29.3 28.4
s.d.¼standard deviation.
aHistory of stroke, hypertension, myocardial infarction, or
diabetes mellitus.
Table 2 Cox proportional hazard ratios (HRs) for prostate cancer incidence by sleep duration in Japanese men
Sleep duration (hours/ per day)
p67 – 8 X9 P for trend
a P for trend
b
Person-years 16716 94786 27104
All prostate cancer
Number of cases 21 87 19
Age-adjusted HR (95% CI) 1.34 (0.83–2.15) 1.00 (reference) 0.46 (0.28–0.75) 0.01 0.0003
Multivariate HR1 (95% CI)
c 1.34 (0.83–2.17) 1.00 (reference) 0.48 (0.29–0.79) 0.02 0.0007
Multivariate HR2 (95% CI)
d 1.38 (0.77–2.48) 1.00 (reference) 0.36 (0.18–0.72) 0.01 0.0009
Localised prostate cancer
Number of cases 4 19 3
Multivariate HR1 (95% CI)
c 1.13 (0.38–3.35) 1.00 (reference) 0.29 (0.09–0.997) 0.11 0.05
Advanced or metastatic prostate cancer
Number of cases 8 25 8
Multivariate HR1 (95% CI)
c 1.82 (0.82–4.05) 1.00 (reference) 0.79 (0.35–1.77) 0.30 0.12
CI¼confidence interval.
aP for trend values were calculated by treating sleep duration as a continuous variable.
bP for trend values were calculated by treating each category of
sleep duration as a continuous variable.
cMultivariate HR1 was adjusted for age (o45, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, and 75+ years old); marital status
(married or unmarried); education (junior high school or less, high school, college/university or higher); job status (employed or unemployed); history of diseases (history of
stroke, hypertension, myocardial infarction, or diabetes mellitus); family history of cancer (presence or absence in first-degree relatives); body mass index (o18.5, 18.5–24.9, or
X25.0kgm
 2); cigarette smoking (never smoked, smoked in the past, currently smoking 1–19 cigarettes per day, or currently smoking X20 cigarettes per day); alcohol
consumption (never drank alcohol, drank in the past, or currently drinking ); walking status (o1h per day or X1h per day).
dMultivariate HR2 was estimated excluding 46
subjects who were diagnosed with prostate cancer within the first 3 years from baseline and was adjusted for using the same variables as in multivariable HR1.
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